Italy

Menu

Home

Home

COVID-19: MENARINI, NEW MADE IN ITALY REAGENT TO ISOLATE VIRAL RNA

Menarini Diagnostics, a company of the Menarini Group, launches the Leasy Kit.

Menarini Diagnostics acquires EOS Preanalytics and Point Of Care company assets

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR^® POC instrument.

On August 20th the German Minister of Health, Jens Spahn visited the Red Cross Hospital of Mölln-Ratzeburg.

First Previous 2 3 4 5 6 7 8 9 10 11 Next

Our values

10 core values have influenced the progress of our group.

A. Menarini Diagnostics s.r.l - Società con socio unico - Sede della società: Via Sette Santi 3 - 50131 Firenze - Numero di iscrizione registro imprese: 05688870483 - Ufficio del registro delle imprese: Firenze
Capitale: € 30.000.000 I.V. - Capitale risultante dall’ultimo bilancio: € 30.000.000 - Società soggetta all’attività di direzione e coordinamento di A. Menarini Industrie Farmaceutiche Riunite Srl.

© 2023 A. Menarini Diagnostics s.r.l - All rights reserved